FDA Approves Immunotherapy-Chemotherapy Combination for Stage III dMMR Colon Cancer

The FDA has approved atezolizumab (Tecentriq) in combination with chemotherapy for adjuvant treatment of stage III deficient DNA mismatch repair (dMMR) colon cancer. This marks the first immunotherapy-based adjuvant regimen for this patient group, offering a 50% reduction in disease recurrence or death. The decision, supported by the phase III ATOMIC trial, represents a significant advancement in treating this specific type of colon cancer.